An analysis of AI-powered devices that received FDA's "breakthrough" label shows a preference for big-picture, multi-problem ...
Alpha DaRT alpha-particle therapy, key 2026 trial catalysts, cash/dilution risks, and M&A takeover potential. See more.
Makower is the Yock family professor of medicine and bioengineering at the Stanford Schools of Medicine and Engineering, and the Byers family director and co-founder of the Stanford Mussallem Center ...
Researchers bio-engineered a tobacco plant to produce five key psychedelic compounds for therapeutic use.